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Abstract
Purpose The serotonin system is undoubtedly involved in
the pathogenesis of major depressive disorder (MDD).
More specifically the serotonin transporter (SERT) serves
as a major target for antidepressant drugs. There are
conflicting results about SERT availability in depressed
patients versus healthy controls. We aimed to measure
SERT availability and study the effects of age, gender and
season of scanning in MDD patients in comparison to
healthy controls.
Methods We included 49 depressed outpatients (mean±SD
42.3±8.3 years) with a Hamilton depression rating scale
score above 18, who were drug-naive or drug-free for
≥4 weeks, and 49 healthy controls matched for age
(±2 years) and sex. Subjects were scanned with single
photon emission computed tomography (SPECT) using
[123I]β-CIT. SERT availability was expressed as specific to
nonspecific binding ratios (BPND) in the midbrain and
diencephalon with cerebellar binding as a reference.
Results In crude comparisons between patients and con-
trols, we found no significant differences in midbrain or
diencephalon SERT availability. In subgroup analyses,
depressed males had numerically lower midbrain SERT
availability than controls, whereas among women SERT
availability was not different (significant diagnosis×gender
interaction; p=0.048). In the diencephalon we found a
comparable diagnosis×gender interaction (p=0.002) and an
additional smoking×gender (p=0.036) interaction. In the
midbrain the season of scanning showed a significant main
effect (p=0.018) with higher SERT availability in winter.
Conclusion Differences in SERT availability in the
midbrain and diencephalon in MDD patients compared
with healthy subjects are affected by gender. The season
of scanning is a covariate in the midbrain. The
diagnosis×gender and gender×smoking interactions in
SERT availability should be considered in future studies
of the pathogenesis of MDD.
Keywords Serotonin transporter . Single photon emission
computed tomography . Depressive disorder . Healthy
control . Gender . Season
Introduction
Major depressive disorder (MDD) is a highly prevalent and
disabling disease, often treated by selective serotonin re-
uptake inhibitors (SSRIs) [1]. SSRIs block the serotonin
transporter (SERT), which lowers the reuptake of serotonin
(5-HT) from the synaptic cleft and increases neurotrans-
mission. Despite the fact that the working mechanism of
antidepressants supports the monoamine deficiency theory,
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the pathogenesis of MDD remains unclear [2, 3]. Therefore,
differences in SERT availability between patients and
healthy subjects have been studied previously.
Post-mortem studies have shown reduced or unchanged
concentrations of SERTs in MDD patients compared with
healthy subjects, but these studies may have been biased by
retrospective data collection, previous antidepressant use,
suicidal behaviour apart from MDD or nonselective ligands
(reviewed by Stockmeier [4]).
Cerebral SERTs in humans can be quantified in vivo
with single photon emission computed tomography
(SPECT) and positron emission tomography (PET). The
first SERT radioligand, 123I-labelled 2β-carbomethoxy-3β-
(4-iodophenyl)-tropane ([123I]β-CIT) binds to both SERTs
and dopamine transporters (DATs) [5]. [123I]β-CIT binding
in the diencephalon and midbrain predominantly reflect
SERTs, while striatal [123I]β-CIT uptake reflects DATs [6].
Studies comparing depressed patients with healthy
subjects have shown decreased [7–13], unchanged [14–
18] or increased [19] SERT availability in MDD patients. A
negative correlation between SERT availability and the
severity of depression, measured in terms of Hamilton
depression rating scale (HDRS) scores, has been reported in
patients with primary MDD [9] or Wilson’s disease [20].
Discrepant results among studies may be explained by
differences in scanning techniques, analytical methods, and
subject sampling, although the effects of additional varia-
bles and their interaction might also explain conflicting
results. Staley et al. reported lower SERT availability in the
diencephalon of female MDD patients than in healthy
subjects [11], and suggested that this interaction accounted
for the contradictory results between studies. Furthermore,
in healthy subjects significant effects on SERT availability
have been reported for gender [21], smoking behaviour
[21], ageing [22, 23] and season of scanning [24, 25].
Our objectives were to quantify SERT availability in
MDD patients in comparison to healthy subjects while
accounting for these potential covariates and possible
interactions, and to correlate SERT availability with the
severity of depression. Therefore, we compared [123I]β-CIT




After receiving approval of the institutional ethics commit-
tee and written informed consent, we recruited depressed
patients from primary care, and our outpatient department
(October 2003 to August 2006). Patients were eligible if
they were 25–55 years old, had a diagnosis of MDD
(diagnosed by structured clinical interview for DSM-IV,
SCID patient version), had a HDRS score of >18, were
antidepressant-free, and were using no more than one
antidepressant (stopped for >4 weeks and ≥5 half-lives of
this antidepressant before scanning) for the present MDD
episode. Exclusion criteria were pregnancy (or desire to
become pregnant), bipolar disorder, psychotic features,
primary anxiety and/or substance abuse disorders, and
acute, severe suicidal ideation. Secondary comorbid anxiety
and/or substance abuse were allowed.
We individually matched each patient by gender and age
(±2 years). Healthy controls were in good physical health
and had never used psychotropic medication. Exclusion
criteria were current or life-time psychiatric disorder(s)
according to the SCID (including abuse or addiction
disorders), a Beck depression inventory (BDI) score of
>9, alcohol use >4 units per day (last month) or a first-
degree relative with psychiatric disorder(s). We allowed the
controls to have incidentally used illicit drugs unless criteria
for a DSM-IV disorder were met, but prohibited illicit drug
use the month prior to scanning. Illicit drug use was not
tested at the time of scanning. Patients and controls
received €50 and €40, respectively. No restrictions were
made with respect to smoking behaviour.
Procedure and SPECT imaging
We performed all scans 230±18 min (mean±SD) after
intravenous injection of approximately 100 MBq [123I]β-
CIT, when the radioligand was at equilibrium for SERT
binding in brain areas expressing high densities of SERTs
[22]. Radiosynthesis of [123I]β-CIT and image acquisition
were as described previously [26]. We performed SPECT
imaging using a 12-detector single slice brain-dedicated
scanner (Neurofocus 810; Strichmann Medical Equipment,
Cleveland, OH) with a full-width at half-maximum resolu-
tion of 6.5 mm, throughout the 20-cm field-of-view. The
Neurofocus system is an upgrade of the SME 810 system
[27], and acquires sequential single transaxial brain
sections. Up to 24 axial sections 5 mm apart were scanned,
and the energy window (140–178 keV) was placed
symmetrically around the 123I gamma energy of 159 keV.
This system uses 800-hole long-bore, point-focused, colli-
mators to obtain high-resolution images.
Image analysis
After attenuation correction (based on an automatically
detected ellipse matching the outer head surface), and
reconstruction in 3-Dmode (based on a maximum a-posteriori
reconstruction), we selected regions of interest (ROIs) for the
midbrain, diencephalon and cerebellum by using validated
templates (Fig. 1) [26]. One examiner (H.G.R.), blinded to
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the diagnosis, positioned all ROIs in two series. Intraclass
correlation coefficients were ≥0.98 for all ROIs. If the two
series differed by >5%, scans were reevaluated by a second
investigator (J.B.). In the analyses the counts for the two
series were averaged.
We assumed that activity in the cerebellum represented
nondisplaceable activity (nonspecific binding and free
radioactivity) [28]. We calculated the binding potential
(BP) as the rate of specific to nondisplaceable (ND) binding
(Z) for midbrain and diencephalon [29]. BPND is propor-
tional to transporter number under equilibrium conditions.
Statistics
General linear models were used to analyse differences in
BPND in the midbrain and diencephalon between depressed
patients and controls using the following modelling
strategy.
We first compared mean BPND between MDD patients
and controls in univariable (‘crude’) models, only contain-
ing the main effect of diagnosis (categorical: MDD/
control). We then fitted multivariable models by adding
variables to the model, which in the literature have been
reported to influence BPND. These variables included:
gender (categorical: male/female), age (continuous), smok-
ing (categorical: yes/no), season of scanning (categorical:
“winter”/“summer”; winter October–March, summer April–
September [24, 25]). In addition, a number of specific two-
way interactions were examined, again because they have
previously been reported to be significant, which included:
diagnosis×gender, diagnosis×smoking, gender×smoking
(‘full multivariable models’) [11, 21]. Three-way interac-
tions were not examined because of the relatively small
sample size (from a statistical perspective). The Akaike’s
information criterion (AIC) was used to judge whether the
two-way interactions improved the model. If a two-way
interaction did not improve the fit of the model, it was
removed from the model in order to facilitate the
interpretation of the model (‘reduced multivariable mod-
els’). Main effects always remained in the model, irrespec-
tive of their significance, in order to report their (lack of)
impact. Diencephalon and midbrain data were analysed
separately, but the same set of variables and interaction
terms were examined using the same modelling approach.
If significant interactions were present, post-hoc analyses
were performed in order to report the absolute differences
in SERT availability in the involved subgroups. Differences
between subgroups were analysed within the framework of
the multivariable model and tested for significance using
the residual variance estimate of the model.
We examined the association of BPND with HDRS
scores using linear regression models in patients, correcting
for covariates used in the multivariable models. We used
SPSS (version 15.0.1) for statistical procedures (http://
www.spss.com). All results are expressed as means±SD,
except in Fig. 2, where ±SEM was used for legibility.
Results
We studied 17 male and 32 female patients with MDD,
versus 17 male and 32 female healthy controls (Table 1).
Significantly more patients than controls smoked (27
patients, 55.1%; 11 controls, 22.4%; χ2=11.2; df 2; p=
0.004). There were significantly more Caucasians among
the controls (n=44; 89.8%) than among the patients (n=31;
63.3%; χ2=11.9; df 3; p=0.008). We scanned 67% of
patients and 55% of controls in winter (χ2=1.55, df 1, p=
0.213). In one female patient insufficient cerebellum was
scanned as a reference, and in three patients and one control
midbrain slices were insufficient; these were omitted from
the analyses. Of 15 patients who had used antidepressants
during their life, 3 had been using antidepressants for the
current episode. One patient had used mirtazapine until
4 weeks before scanning; all others had stopped antide-
pressants 6–132 months before scanning. Illicit drug abuse
Fig. 1 Examples of SPECT
images after 3-D reconstruction
showing the ROIs for the mid-
brain, cerebellum and dienceph-
alon. Templates with fixed ROIs
are shown in green. a Midbrain
(circle) and cerebellum. b Stria-
tum (for midbrain–diencephalon
demarcation) and diencephalon
(circle). ROIs were positioned
by hand based on anatomy and
maximum concentration of ac-
tivity per millilitre in the ROI
Eur J Nucl Med Mol Imaging (2009) 36:841–849 843
Table 1 Baseline characteristics of MDD patients and healthy controls (stratified by gender)
MDD patients Healthy controls
Male (n=17) Female (n=32) Male (n=17) Female (n=32)
Age (years) 43.2±7.8 41.8±8.6 43.0±8.1 41.9±8.9
Current cigarette smokers; n (%)a 12 (70.6) 15 (46.9) 3 (17.6) 8 (25.0)
Alcohol use >8 units/week; n (%) b 3 (17.6) 4 (12.5) 7 (41.2) 8 (25.0)
Race: n (%)
Caucasian 12 (70.6) 19 (59.4) 15 (88.2) 29 (90.6)
Creole 2 (11.8) 7 (21.9) 2 (11.8) 3 (9.4)
Asian 2 (11.8) 5 (15.6) 0 0
MDD
Severityc 23.2±4.9 25.4±4.7 1.3±1.4 2.0±2.1
First episode; n (%) 9 (52.9) 18 (56.3) N/A N/A
Drug-naive; n (%) 12 (70.6) 22 (68.8)
Melancholic; n (%) 12 (70.6) 24 (75.0)
Atypical; n (%) 0 3 (9.4)
Suicidal thoughts, plan or attempt; n (%) 7 (41.2) 10 (31.3)
Duration of episode; n (%)
<5 months 5 (29.4) 8 (25.0)
5 months to 2 years 8 (47.1) 21 (65.6)
>2 years 4 (23.5) 3 (9.4)
Age at first episode (years) 35.9±10.3 35.8±10.4
Comorbidity: n (%)
Anxiety disorder 4 (23.5) 7 (21.9) N/A N/A
Dysthymia 1 (5.9) 1 (3.1)
Alcohol dependence 1 (5.9) 3 (9.4)
Drug (alcohol, cannabis, benzodiazepines) abuse 4 (23.5) 3 (9.4)
SPECT scan in winter; n (%) 9 (52.9) 24 (75.0%) 7 (41.2) 20 (62.5)
a Significantly more MDD patients than controls smoked (χ2 =11.0; 1 df; p<0.01).
b Trend for lower alcohol use in MDD patients than in controls (χ2 =3.75; 1 df; p=0.053)
c Severity measured using the HDRS (17 items) in MDD patients and the BDI in controls.
Fig. 2 BPND values for the midbrain and diencephalon. Multivariable
models for BPND in MDD patients (MDD) versus healthy controls
(HC) stratified for gender. Values are estimated means ±SEM.
a Midbrain (n=94), corrected for main effects of diagnosis (p=0.414),
gender (p=0.128), season of scanning (F1,87=5.814; p=0.018), smoking
(p=0.582), age (p=0.227) and diagnosis×gender interaction
(F1,87=4.039; p=0.048). *Post-hoc differences t87=−1.718; p=0.089
between: MDD males and control males. b Diencephalon (n=97),
corrected for main effects of diagnosis (p=0.476), gender (p=0.277),
season of scanning (p=0.679), smoking (p=0.223), age (p=0.247) and
diagnosis×gender interaction (F1,88=10.227; p=0.002), gender×
smoking interaction (F1,88=4.541; p=0.036) and diagnosis×smoking
interaction (p=0.127). *Post-hoc difference t88=−2.384; p=0.019
between smoking male controls and nonsmoking male controls.
**Post-hoc differences t88>2.643; p<0.01 between: smoking male
MDD patients and smoking male controls, nonsmoking female MDD
patients and nonsmoking female controls
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mainly involved cannabis. Life-time MDMA use occurred
in none of the patients and in one female control (fewer
than ten tablets; last use 8 months before scanning).
SERT availability in MDD patients versus healthy controls
(‘crude models’)
Midbrain BPND in patients (0.62±0.22) was not signifi-
cantly different from that in controls (0.63±0.19;
F1,94=0.118; p=0.733). Diencephalon BPND was 1.15±
0.24 in patients and 1.09±0.26 in controls (F1,97=1.209; p=
0.274).
Multivariable models of SERT availability in MDD patients
versus healthy controls
Midbrain
For the midbrain, the full multivariable model (including
diagnosis, gender, age, smoking, season of scanning,
diagnosis×gender, diagnosis×smoking, and gender×smoking)
was subsequently reduced by removing the nonsignificant
interaction terms diagnosis×smoking and gender×smoking
(AIC decrease 2.478; Fig. 2a). This reduced multivariable
model showed a significant diagnosis×gender interaction
(F1,87=4.039; p=0.048). In post-hoc comparisons, MDD
males showed a trend for lower BPND compared with male
controls (difference −0.124; t87=−1.718; p=0.089), while
female patients and controls did not differ significantly
(difference 0.047; t87=0.898; p=0.372). Furthermore, the
main effect of season of scanning was significant
(F1,87=5.814; p=0.018). Scans performed in winter showed
on average 18% higher BPND than scans performed in
summer (F2,87=3.248; p=0.044). The main effects of age
and smoking were also included in this reduced model, but
were not significant (p=0.227 and p=0.582, respectively;
Fig. 2a).
Diencephalon
For the diencephalon, the full multivariable model (includ-
ing the same variables as for the midbrain) could not be
reduced, as all three interaction terms (diagnosis×smoking,
diagnosis×gender and smoking×gender) improved the fit of
the model as evaluated by the AIC (Fig. 2b). This full
multivariable model showed significant diagnosis×gender
(F1 , 88=10.227; p = 0.002) and smoking×gender
(F1,88=4.541; p=0.036) interactions. The diagnosis×smok-
ing interaction was not significant (p=0.127). In post-hoc
comparisons, smoking male MDD patients had significant-
ly lower BPND than smoking male controls (difference
−0.304; t88=−2.643; p=0.010). In nonsmoking male MDD
patients, BPND was numerically lower than in nonsmoking
male controls (difference −0.140; t88=−1.340; p=0.184). In
contrast, nonsmoking female patients had higher BPND than
nonsmoking female controls (difference 0.221; t88=3.064;
p=0.003) with almost no difference in BPND between
smoking female MDD patients and controls (difference
0.057; t88=0.616; p=0.539). Furthermore, smoking male
controls had significantly higher BPND than nonsmoking
male controls (difference 0.279; t88=−2.384; p=0.019),
while in female controls, BPND was not affected by
smoking (difference 0.032; t88=−0.371; p=0.712). The
main effects of season of scanning and age were also
included in this model, but were not significant (p=0.679
and p=0.247, respectively; Fig. 2b).
Relationship between SERT availability and severity
of MDD
Linear regression models showed no significant relation-
ship between HDRS scores and BPND, either in the
midbrain or in the diencephalon when taking into account
gender, age, smoking and season of scanning.
Discussion
In the present – until now largest – study of MDD patients
in comparison to healthy subjects, we aimed to quantify
SERT availability in MDD patients and healthy subjects
while taking into account covariates and interactions, and
to determine the degree correlation between SERT
availability and depression severity. We did not find
significant differences in SERT availability in the mid-
brain or diencephalon in crude comparisons. However, a
significant diagnosis×gender interaction was found in the
midbrain and diencephalon, combined with a significant
gender×smoking interaction in the diencephalon only.
Depressed males, but not females, had lower midbrain
SERT availability than healthy controls. In the dienceph-
alon smoking male MDD patients had significantly lower
SERT availability than smoking male controls, while
nonsmoking female patients had higher SERT availability
than nonsmoking female controls. Furthermore, the season
of scanning influenced SERT availability in the midbrain,
with higher SERT availability in winter. We found no
clinically relevant correlation between HDRS scores and
SERT availability.
Comparison with previous studies
Our results confirm previous reports of similar SERT
availability in the midbrain and diencephalon in MDD
patients and healthy subjects [14–18]. Other studies have
shown increased [19] or decreased [7–13] SERT availability
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in MDD patients compared with healthy subjects. However,
none of these studies except two [11, 13] investigated the
effect of gender, and none of the study corrected for season.
Furthermore, we confirmed a significant contribution of
season of scanning on midbrain BPND [24].
The diagnosis×gender interaction in the midbrain and
diencephalon is our most important finding. In contrast to
the findings of Staley et al. [11, 21], we found a different
direction of this interaction in the diencephalon: signifi-
cantly lower BPND in male MDD patients in the midbrain
(−17%) and diencephalon (−18%), and higher BPND in
female MDD patients in the midbrain (+9%, nonsignificant)
and diencephalon (+13%, significant) than in healthy
subjects. Staley et al. found 1% lower SERT availability
in the diencephalon in male MDD patients, and 22% lower
SERT availability in the diencephalon in female MDD
patients. We found a gender×smoking interaction in the
diencephalon (with highest BPND in smoking male healthy
controls), while Staley et al. found higher SERT availability
in the brainstem (attributable to males). Our findings
suggest that a failure to stratify for a diagnosis×gender
interaction may obscure differences between patients and
healthy subjects.
Methodological explanations for inconsistent findings
Despite technical differences between studies (scanning
protocols, radioligands, image analyses), variation in the
selection of healthy controls (e.g. having relatives with
psychiatric diagnoses) or patients (from different source
populations) is the most probable explanation for the
inconsistent findings. Previous studies recruited patients
from general psychiatric outpatient and university clinics
[7, 8, 10, 12, 18, 19, 30]. We recruited 65% of our patients
from primary care settings. We adequately diagnosed
patients by SCID, and required an HDRS score of >18 for
inclusion. Thus, we recruited severely affected and often
melancholic patients who were drug-free, with 69% of the
patients being drug-naive. Three studies [7, 13, 31]
included larger proportions of drug-naive patients. Like
Parsey et al. [10], we observed (nonsignificant −15%)
lower midbrain SERT availability in drug-naive patients
(results available on request). Additionally, some studies
have suggested that anxiety disorders influence SERT
availability [32], and MDD with comorbid anxiety may
differ from ‘pure MDD’. However, this was not observed in
our sample (results available on request).
Role of SERT in the pathogenesis of MDD
SERTs evacuate extracellular 5-HT from the synapse.
Observed differences in SERTs between patients and
healthy subjects may represent differences in the number
of SERT-containing neurons, in the number of SERTs per
neuron or a combination of both.
Two major mechanisms for the role of SERT in MDD
have been hypothesized [32]. First, increased SERT
availability reduces 5-HT from the synapse more easily,
which might lower 5-HT transmission, possibly leading to
MDD. Second, as the brain might apply compensation
mechanisms to retain homeostasis, a decreased 5-HT
transmission as a result of MDD may result in down-
regulation (decrease) of SERT in order to increase 5-HT
transmission. A sequential occurrence of these two mech-
anisms could also be hypothesized: an initially increased
SERT availability destabilizes (with or without an addition-
al factor) and leads to MDD, which is followed by a
decrease in SERT to compensate for decreased 5-HT
transmission.
Differential effects of MDD on SERT availability between
sexes may be explained via sex hormones. Oestrogen
replacement after ovariectomy has been shown to increase
SERT mRNA and SERT availability in female rats [33] and
in hypothalamic regions of female macaques [34]. Depressed
women may have significantly higher 24-h mean levels of
diurnal oestradiol rhythms, and may have higher testosterone
levels than healthy individuals [35]. Testosterone may
increase SERT availability by conversion to oestrogen by
aromatase, which is especially available in the diencephalon.
This could explain our finding of increased SERT availability
in the diencephalon in females. In depressed men, the sex
steroid testosterone is decreased [35], with 34–61% bio-
chemical hypogonadism in depressed males compared with
6–14% in healthy individuals [36]. This lack of testosterone
in MDD may reduce SERT availability as a result of reduced
conversion to oestrogen. Replacement of testosterone in
castrated male rats increases SERT mRNA and SERT
availability [37]. Since we did not measure sex hormones,
and Best et al. [38] found no relationship between menstrual
cycle or sex hormones and SERT availability in healthy
individuals, these explanations remain speculative and
should be examined further.
We confirmed a main effect of season demonstrated
previously in the diencephalon in 12 healthy women [39]
and the mesencephalon in 29 healthy individuals [24] and
various brain regions in 88 healthy individuals [25].
Neumeister et al. observed decreased SERT availability in
winter [39]. In contrast, Buchert et al. [24] and Praschak-
Rieder et al. [25] found increased SERT availability in
winter, which was also found in our study. Serotonin
modulates the effects of photic input in the suprachiasmatic
nucleus (SCN). The SCN imposes a circadian rhythm by
affecting hormonal and autonomic output (reviewed by
Buijs et al. [40]). Serotonin release in the SCN is highest
during waking and activity [41]. Because raphe neurons
show regular high firing rates during waking and decreased
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firing during sleep, it could be hypothesized that during
winter, with decreased daylight, more serotonergic activity
is needed, which may be mediated via the raphe input into
the SCN [42]. Increased serotonergic activity (increased
free synaptic serotonin) may result in a compensatory
increase in SERTs. Nevertheless, the small size of the SCN
(about 0.27 mm3) by itself cannot explain higher SERT
availability found by SPECT or PET.
Limitations of the present study
The cerebellum (especially the vermis) contains small
amounts of SERT [43, 44], which could result in an
underestimation of BPND in patients and healthy controls,
expected to be 7% at most [45]. [123I]β-CIT binds in vivo
to SERT, DAT and norepinephrine transporters. Conse-
quently, a systematic underestimation of SERT assessment
due to increased DAT or norepinephrine transporters in the
midbrain (substantia nigra and locus coeruleus, respective-
ly) cannot be ruled out. Although recently Yang et al.
measured a small but significant increased striatal DAT
binding with [99mTc] TRODAT-1 SPECT in 10 MDD
subjects versus 10 controls [46], we think the potential
systematic underestimation of midbrain SERT is unlikely to
explain the observed gender interactions between patients
and healthy controls.
Second, lower levels of endogenous 5-HT (e.g. in MDD)
could result in less competition with radioligands, increas-
ing the specific binding measured. This has been demon-
strated in rhesus monkeys with [123I]β-CIT SPECT [47] but
not in humans. After tryptophan depletion (artificially
reducing endogenous 5-HT) no differences in SERT
availability were observed [48, 49] but the radioligand
([11C]DASB) in that study does not bind to the 5-HT
recognition/translocation site, and may not be suitable for
imaging such changes in extracellular 5-HT [50]. Third, we
used previously validated ROIs [26] instead of magnetic
resonance imaging for coregistration. Because these tem-
plates cover larger brain areas, BPND in small regions
(raphe nuclei) cannot be determined. This potential mea-
surement error (nondifferential for patients and controls),
might have increased variance in our measurements, despite
very good intrarater correlation coefficients. Additionally,
we did not correct for nonuniform photon attenuation and
partial volume effects in our gender analyses. Greater skull
thickness might have led to an underestimation of BPND in
males, and a smaller midbrain and diencephalon in females
might have led to suppression of BPND compared with
males. In future studies hybrid SPECT/CT may be useful to
correct for nonuniform attenuation and better delineate the
midbrain and diencephalon by anatomical–functional cor-
relation. However, these factors are unlikely to explain the
observed interactions in this study.
Fourth, the 4-week washout of antidepressants (binding
to SERT) may have been too short [51]. Because all but one
patient stopped antidepressants ≥6 months before scanning,
we think no substantial bias in the BPND assessment was
introduced by competitive binding by traces of previous
antidepressants. Fifth, we allowed previous incidental use
of illicit drugs (marijuana/cannabis in ten subjects, MDMA
in one subject) in our controls. Because heavy use of
MDMA (>50 MDMA tablets) can damage serotonin
neurons [52], we performed an additional analysis in which
we excluded data from the MDMA user in the control
group. However, this exclusion did not affect our results
(results available on request). Sixth, we did not check
personal or family history of psychiatric illnesses among
the controls, nor did we test for alcohol or drug abuse.
Conclusion
We showed lower SERT availability in the midbrain and
diencephalon in depressed males and higher SERT avail-
ability in the diencephalon in depressed (nonsmoking)
females compared with healthy controls. We confirmed a
seasonal influence on midbrain SERT availability, and
found a gender×smoking interaction in diencephalon SERT
availability. This study points to complex effects of gender,
smoking and season on the serotonergic system in the
pathogenesis of MDD.
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